Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation
Summary
The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of bicarbonate (HCO3-) excursions compared to the use of Phoxilium® during the studied continuous veno-venous hemofiltration (CVVH) interval with regional citrate anticoagulation (RCA). The secondary objectives of the BiPhox-Trial are to evaluate the time to pH level normalization and the HCO3- substitution rates after initiation of CVVH treatment. Further, to demonstrate that the use of Biphozyl® as a replacement fluid in adult critically ill AKI patients, results in a more stable acid-base-status as well as improved respiratory situation due to lower intracorporeal HCO3- and carbon dioxide levels compared to the use of Phoxilium® during the studied CVVH interval with RCA.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2023-11-15
- Completion
- 2024-03-11
Outcome
Met primary endpoint
paper LBF showed significantly lower rates of pH and HCO3- excursions compared to HBF PMID 41247497 ↗
paper Adjusted odds ratios were 1.78 (95% CI 1.12-2.82; p = 0.015) for pH and 3.60 (95% CI 2.16-5.99; p < 0.001) for HCO3-. PMID 41247497 ↗
Publications
- Perschinka F, Koglberger P, Kohler A, Lehner GF, Peer A, Maier S, Ulmer H, Bellmann R, Forni LG, Joannidis M. Comparison of two different bicarbonate replacement fluids during CVVH with RCA: a prospective, randomized, controlled trial. Intensive Care Med. 2025 Dec;51(12):2354-2366. doi: 10.1007/s00134-025-08175-7. Epub 2025 Nov 17.
- Koglberger P, Perschinka F, Klein SJ, Mayerhofer T, Maier S, Ulmer H, Bellmann R, Joannidis M. Protocol of the Comparison of Two Different Bicarbonate Replacement Fluids during Continuous Veno-Venous Hemofiltration with Regional Citrate Anticoagulation: A Prospective, Randomized, Controlled Trial. Blood Purif. 2025;54(12):723-732. doi: 10.1159/000547401. Epub 2025 Aug 4.